There is an impressive number of obesity management medications under investigation, such as GLP1/glucagon dual agonists, GIP/GLP1 dual agonists, GIP/GLP1/glucagon tri-agonists, leptin sensitizers, etc. [9]. The gene discussed is GIP; the disease is obesity disorder.